

**Supplementary Figure 1:** Comparison of residual IFX trough levels between IBD patients in clinical remission and those with active disease (eg. patients who lost response to IFX) (**Supplementary Figure 1a:**  $p < 0.0001$ ,  $N=103$ ): results in CD patients (**Supplementary Figure 1b:**  $p < 0.0001$ ,  $N=55$ ) and in UC patients (**Supplementary Figure 1c:**  $p=0.0112$ ,  $N=48$ ).

